Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2023Blood AdvancesOpen Access

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGemma ReynoldsECEdward R. Scheffer CliffGMGhulam Rehman Mohyuddin

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reynolds et al. (2023) studied this question.

synapsesocial.com/papers/69ddc814da08968cf7b0bd29https://doi.org/10.1182/bloodadvances.2023010539
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study2022 · 40 citations
  2. 2Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma2022 · 5 citations
  3. 3A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)2020 · 113 citations
  4. 4Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study2021 · 167 citations
  5. 5The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2020 · 5,397 citations